A proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug

BACKGROUND AND PURPOSE: ATB‐346 is a hydrogen sulfide (H(2)S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Pharmacol
Autores principales: Wallace, John L., Nagy, Peter, Feener, Troy D., Allain, Thibault, Ditrói, Tamás, Vaughan, David J., Muscara, Marcelo N., de Nucci, Gilberto, Buret, Andre G.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Themed Section: Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7024706/
https://ncbi.nlm.nih.gov/pubmed/30834513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14641
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares